Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.00 +1.1%	$9.48	$3.25 ▼ $14.44	$765.58M	0.94	1.26 million shs	768,025 shs
CDMO Avid Bioservices	$12.50 +0.1%	$12.46	$5.90 ▼ $12.51	$799.18M	1.39	1.25 million shs	3.07 million shs
CRON Cronos Group	$1.86 -1.6%	$1.96	$1.83 ▼ $3.14	$711.51M	0.89	1.73 million shs	1.15 million shs
HURA TuHURA Biosciences	$1.98 -5.7%	$3.86	$1.80 ▼ $14.60	$83.72M	1.02	194,652 shs	102,094 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+1.12%	+4.77%	+8.56%	+6.38%	+67.29%
CDMO Avid Bioservices	0.00%	0.00%	0.00%	+1.26%	+99.92%
CRON Cronos Group	-1.59%	-7.46%	-5.58%	-3.63%	-7.92%
HURA TuHURA Biosciences	-5.71%	-2.94%	-55.80%	-59.84%	+197,999,900.00%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.957 of 5 stars	3.7	1.0	0.0	4.7	3.4	0.8	0.6
CDMO Avid Bioservices	0.987 of 5 stars	1.0	0.0	0.0	4.5	0.0	2.5	0.6
CRON Cronos Group	1.5706 of 5 stars	2.5	3.0	0.0	0.0	2.1	0.0	1.3
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	388.89% Upside
CDMO Avid Bioservices	2.00	Hold	$12.25	-1.96% Downside
CRON Cronos Group	1.00	Sell	$3.00	61.29% Upside
HURA TuHURA Biosciences	3.25	Buy	$13.00	556.57% Upside

Current Analyst Ratings Breakdown

Latest HURA, CDMO, AVXL, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/3/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
2/18/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
2/12/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
1/28/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
1/28/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
1/21/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
1/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
12/26/2024	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $42.00
12/23/2024	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
12/19/2024	HURA TuHURA Biosciences	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/19/2024	HURA TuHURA Biosciences	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$11.00

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CDMO Avid Bioservices	$139.91M	5.71	$0.15 per share	80.92	$3.02 per share	4.14
CRON Cronos Group	$117.62M	6.05	N/A	N/A	$2.87 per share	0.65
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	($4.11) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	5/8/2025 (Estimated)
CDMO Avid Bioservices	-$140.75M	-$2.39	N/A	N/A	N/A	-101.07%	-33.18%	-8.45%	4/23/2025 (Estimated)
CRON Cronos Group	-$73.96M	$0.10	N/A	62.00	1.74	-42.65%	-2.56%	-2.47%	5/8/2025 (Estimated)
HURA TuHURA Biosciences	-$8.32M	N/A	0.00	∞	N/A	N/A	N/A	-152.88%	3/19/2025 (Estimated)

Latest HURA, CDMO, AVXL, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/19/2025	N/A	HURA TuHURA Biosciences	-$0.09	N/A	N/A	N/A	N/A	N/A
2/12/2025	Q1 2025	AVXL Anavex Life Sciences	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A
12/23/2024	Q4 2024	AVXL Anavex Life Sciences	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CDMO Avid Bioservices	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
CDMO Avid Bioservices	3.58	1.30	0.92
CRON Cronos Group	N/A	24.24	23.05
HURA TuHURA Biosciences	N/A	1.54	1.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
CDMO Avid Bioservices	97.16%
CRON Cronos Group	8.71%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
CDMO Avid Bioservices	3.05%
CRON Cronos Group	6.90%
HURA TuHURA Biosciences	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.06 million	75.71 million	Optionable
CDMO Avid Bioservices	320	63.96 million	62.01 million	Optionable
CRON Cronos Group	450	382.53 million	356.14 million	Optionable
HURA TuHURA Biosciences	N/A	42.29 million	42.20 million	N/A

HURA, CDMO, AVXL, and CRON Headlines

Recent News About These Companies

TuHURA Biosciences appoints Craig Tendler to board of directors

March 11 at 7:32 PM | markets.businessinsider.com

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

March 11 at 8:05 AM | accessnewswire.com

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

March 10, 2025 | gurufocus.com

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

March 10, 2025 | accessnewswire.com

What is HC Wainwright's Forecast for HURA Q2 Earnings?

March 8, 2025 | americanbankingnews.com

Q2 Earnings Estimate for HURA Issued By HC Wainwright

March 7, 2025 | marketbeat.com

TuHURA Biosciences (NASDAQ:HURA) and Its Position in the Immuno-Oncology Market

March 5, 2025 | kalkinemedia.com

HC Wainwright Begins Coverage on TuHURA Biosciences (NASDAQ:HURA)

March 5, 2025 | americanbankingnews.com

TuHURA Biosciences initiated with a Buy at H.C. Wainwright

March 4, 2025 | markets.businessinsider.com

Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 10.37%

March 4, 2025 | aaii.com

HC Wainwright & Co. Initiates Coverage of TuHURA Biosciences (HURA) with Buy Recommendation

March 4, 2025 | msn.com

TuHURA Biosciences (NASDAQ:HURA) Earns Buy Rating from Analysts at HC Wainwright

March 3, 2025 | marketbeat.com

Suncoast Equity Management Buys Shares of 102,997 TuHURA Biosciences (NASDAQ:HURA)

February 22, 2025 | marketbeat.com

TuHURA Biosciences (HURA) to Release Earnings on Wednesday

February 21, 2025 | marketbeat.com

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025 | accessnewswire.com

TuHURA Biosciences: A Hold On Only The Faintest Glimmers Of Efficacy

February 16, 2025 | seekingalpha.com

Apollon Wealth Management LLC Acquires New Stake in TuHURA Biosciences (NASDAQ:HURA)

February 15, 2025 | marketbeat.com

Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger

February 10, 2025 | fiercebiotech.com

HURA: Initiating an Immune Response

February 5, 2025 | msn.com

Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Up 17.17%

January 30, 2025 | aaii.com

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

January 18, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, CDMO, AVXL, and CRON Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.00 +0.10 (+1.12%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$9.06 +0.05 (+0.61%)

As of 03/13/2025 07:59 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Avid Bioservices NASDAQ:CDMO

$12.50 +0.02 (+0.12%)

Closing price 02/5/2025

Extended Trading

$12.50 0.00 (0.00%)

As of 02/5/2025 04:23 PM Eastern

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Cronos Group NASDAQ:CRON

$1.86 -0.03 (-1.59%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$1.87 +0.01 (+0.54%)

As of 03/13/2025 07:58 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

TuHURA Biosciences NASDAQ:HURA

$1.98 -0.12 (-5.71%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$2.05 +0.07 (+3.48%)

As of 03/13/2025 07:56 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time